Navigation Links
Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
Date:3/10/2011

ponse Letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements  

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to conduct a preapproval cardiovascular outcomes trial, Orexigen's ability to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an ND
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), maker of ... Andrew J. Whelan , President will be interviewed ... Business" at 9am EDT on Wednesday, August 5 th ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. ... the company,s flagship product, ActiPatch Therapy, is achieving in ...
(Date:8/3/2015)... Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today ... 2015 Investor Conference Call and webcast at 4:30 p.m., Eastern ... will cover an update on Merrimack,s progress as well ... press release detailing the information to be discussed on ... August 10. Investors and the general public are invited ...
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3
... 12 A,groundbreaking study developed by Breastcancer.org reports that ... information and messaging,around breast cancer. This study surveyed ... findings from this research revealed that nearly 30% of ... development was a symptom of,breast cancer, and more than ...
... VRUS ), a clinical stage pharmaceutical company committed ... financial results for the fiscal year ended September 30,2008. At ... cash,equivalents and short term investments. , ... Clevudine , ...
Cached Medicine Technology:New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement 2Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9
(Date:8/3/2015)... ... August 03, 2015 , ... ... the largest online retailer of nutritional supplements, has officially opened the polls ... 11 awards in the following categories:, ,     Brand of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s ... 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award ... organization whose mission is to develop technology for the sake of humanity – ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing and cooking food comes ... at a young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now ... Recipes from My Persian Kitchen with the world. , Since Americans tend to be ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its least visited ... untapped ground water aquifers, whose main outflow is at Ahjumawi Lava Springs, part ...
Breaking Medicine News(10 mins):Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4
... a greater risk , than they might think SCHAUMBURG, ... 1 million cases of skin cancer ... historically those most at risk for developing skin cancer are ... generally older populations, dermatologists advise that those who do not ...
... A new survey from Noblis Health Innovation, a leading ... of the current economic crisis, nearly a third of hospitals are ... in April 2009, the affiliation study is the first in a ... Insights Panel , a collection of more than 150 leading health ...
... 2009A new review finds hospital volume to be a ... studies, when combined, show a quantifiable and statistically significant ... finds that individual studies often fail to show such ... at best an imperfect proxy for healthcare quality. , ...
... implicated in cardiovascular disease risk for 5000 years. ... investigators from Germany at the University of Erlangen, ... Berlin-Buch and Regensburg, collaborating with researchers from Finland ... relationship between salt intake, bodily processes, and blood ...
... Millennium Research Group releases latest editions of its ... the cardiovascular, endoscopy, orthopedics, aesthetics, and imaging and ... Research Group (MRG), the global authority on medical ... 2009 issues of its Industry Quarterly (IQ) ...
... and not drinking enough water are to blame.ANN ARBOR, ... call from her daughter,s daycare saying that 3-year-old Emma ... cause would be a condition often associated with middle ... over in pain and saying that her back hurt ...
Cached Medicine News:Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 2Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 3Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 4Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 5Health News:Noblis Insights Panel Finds Growing Interest in Hospital Affiliation as a Strategic Response to Challenging Market Conditions 2Health News:Noblis Insights Panel Finds Growing Interest in Hospital Affiliation as a Strategic Response to Challenging Market Conditions 3Health News:Hospital volume inconsistent predictor of quality care 2Health News:New light shed on the enigma of salt intake and hypertension 2Health News:Despite the Economic Downturn, Long-Term Growth Potential in the US Dental Biomaterial Market Remains Robust 2Health News:Kidney Stones in Children on The Rise, U-M Expert Says 2Health News:Kidney Stones in Children on The Rise, U-M Expert Says 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: